PULM Pulmatrix, Inc.

NASDAQ
$1.54

Pulmatrix, Inc. (PULM) is expected to report earnings on November 12, 2026, before the market open.

Pulmatrix, Inc. Reported Earnings
Thursday, August 13, 2026 · 8:15 AM ET
Earnings Date
Nov 12
Thursday · 8:05 AM ET
Earnings Whisper
-
vs -
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP -

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Pulmatrix, Inc.

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for serious lung diseases such as allergic bronchopulmonary aspergillosis ("ABPA") and lung cancer, as well as neurologic disorders such as acute migraine.

Sector

Healthcare

Industry

Biotechnology